Temporary extracorporeal left ventricular assist device support for implantable left ventricular assist device replacement cases  by Schechter, Matthew A. et al.
Case Reportsaortic debranching by reducing both the number of anasto-
moses and the risk of bleeding.
Neurologic protection is a main concern during arch and
thoracoabdominal aortic procedures. If antegrade selective
cerebral perfusion has already shown to be the best method
of brain protection,2 more recent experimental and clinical
studies have introduced the collateral network concept to
comprehend spinal vascular remodeling after extensive
thoracoabdominal aortic interventions. This notion indi-
cates that restoring a good spinal cord perfusion is a
time-dependent process and supports staged thoracoabdo-
minal aortic repair to reduce the incidence of postoperative
spinal cord injury.3 Furthermore, relative to single-staged
procedures, which combine at once the detrimental effects
of visceral ischemia with those of nephrotoxic contrast
media, staged repair seem to be associated with reduced
postoperative renal failure rates and shorter hospital stay.4
We were well aware that a patient’s failure to complete
treatment (as result of death while waiting or refusal) repre-
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In conclusion, a staged hybrid approach for total aortic
repair is feasible and can represent a valid form of treatment
for selected patients with extensive aortic disease. It may
help reduce morbidity and mortality among these high-
risk patients.
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for implantable left ventricular assist device replacement casesMatthew A. Schechter, MD,a Chetan B. Patel, MD,b Joseph G. Rogers, MD,b and Carmelo A. Milano, MD,a
Durham, NCReplacement of an implantable left ventricular assist device
(LVAD) may be required for infection, thrombosis, or me-
chanical or electrical failure.1,2 In certain instances,
replacement of implantable LVADs poses a very high risk
of either reinfection or death. This report describes 4
cases in which implantable LVADs required urgent
removal but replacement of an implantable system was
delayed by a period of support with an extracorporeal
temporary device.CLINICAL SUMMARY
The first patient was a 58-year-old woman with
ischemic cardiomyopathy who had received a HeartMate
II (Thoratec Corporation, Pleasanton, Calif) as destination
therapy. The patient presented approximately 18 months
after implantation with persistent bacteremia and medias-
tinal purulence. Echocardiography showed vegetation
around the inflow cannula. The decision was made to re-
move the device. Because of the extent of infection, the
patient was supported with an extracorporeal device (Para-
corporeal Ventricular Assist Device [PVAD]; Thoratec)
while receiving antibiotic therapy. After 3 weeks of antibi-
otics, the patient had negative results of blood cultures and
a normal white blood cell count. She was returned to the
operating room, where the Thoratec PVAD was replaced
with another HeartMate II device. The patient did well
postoperatively and went on to live for approximately 3
years without any further episodes of bacteremia or other
evidence of device infection.
The second patient was a 63-year-old man who
presented with recurrent fevers and staphylococcal bacter-
emia despite intravenous antibiotics 1 year after receivingery c April 2014
FIGURE 1. Lateral chest radiographs from the same patient (patient 4) with VentrAssist (A), Thoratec PVAD (B), and HeartMate II (C) left ventricular
assist devices in place.
Case Reportsa HeartMate II for ischemic cardiomyopathy. When the
patient was taken to the operating room for pump ex-
change, purulence was noted in the anterior mediastinum
and pump pocket. The patient also had significant vasople-
gia, requiring multiple pressors. The patient therefore
received a CentriMag LVAD (Thoratec) for support
instead of another implantable device. Unfortunately, the
patient continued to demonstrate hemodynamic instability
postoperatively, progressing to multiorgan system failure.
Although the bacteremia eventually resolved, the patient’s
condition was considered to be too unstable for him to
receive an implantable system, and he died within 2 weeks
of the HeartMate II removal.
The third patient was a 60-year-old woman who
received a HeartMate II LVAD as destination therapy for
nonischemic cardiomyopathy. Unfortunately, the patient
experienced multiple episodes of hemolysis requiring 2
separate HeartMate II replacements within 18 months of
the initial procedure. Five months after her second ex-
change, she presented with severe hemolysis, oliguria,
and pump dysfunction. Although echocardiography
showed moderately improved left ventricular systolic
function, she had acute renal failure, due in part to hemo-
lysis. The patient was taken to the operating room for
HeartMate II removal, and a CentriMag LVAD was placed
for the purposes of determining whether the patient might
be a candidate for LVAD weaning. Although efforts to
wean her from the CentriMag were unsuccessful, her renal
function eventually normalized. She then had the Centri-
Mag exchanged for an implantable system. Because of
her recurrent issues with the HeartMate II, an HVAD sys-
tem (HeartWare Inc, Framingham, Mass) was used. The
patient did well postoperatively and did not have further
hemolysis.
The last patient was a 30-year-old woman who required
a VentrAssist LVAD (VentraCor, Sydney, Australia) forThe Journal of Thoracic and Canonischemic cardiomyopathy. Approximately 2 weeks
after the implant procedure, she had increased LVAD po-
wer consumption, presumably from pump thrombosis. She
soon became hypotensive and oliguric despite multiple
pressors and an intra-aortic balloon pump. She was there-
fore taken urgently to the operating room for removal of
the thrombosed pump. Intraoperatively, both ventricles
were markedly dilated and dysfunctional, with no apparent
flow through the VentrAssist outflow graft. The VentrAs-
sist device was removed, and a temporary extracorporeal
Thoratec PVAD was placed (Figure 1). After the patient’s
condition stabilized with Thoratec PVAD support during
the course of several weeks, she returned to the operating
room for successful exchange of the PVAD for a Heart-
Mate II (Figure 1).
DISCUSSION
Some patients requiring device exchanges can present
with such extreme cardiovascular compromise or high like-
lihood of reinfection that replacement with another implant-
able system would be a risky or even futile procedure.
Placement of an extracorporeal device, however, is easier
and less expensive than replacement with an implantable
system.3 In this series, we present 4 cases in which highly
unstable patients requiring device explantation were sup-
ported with extracorporeal ventricular assist systems. This
temporary support with an extracorporeal device allowed
for determination of the feasibility and appropriateness of
another implantable device. In 3 of the cases, after 3 weeks
of clinical stability or antibiotic treatment, the patients
recovered enough to receive an implantable system with
successful long-term outcomes.
CONCLUSIONS
In the case of a highly unstable or persistently bacteremic
patient in need of urgent LVAD removal, an interval ofrdiovascular Surgery c Volume 147, Number 4 e47
Case Reportssupport with an extracorporeal temporary device may be
appropriate.
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therapy. Circ Heart Fail. 2012;5:10-6.Recurrent esophagopericardial fistula in a patient with human
immunodeficiency virusLloyd M. Felmly, BS, Walter F. DeNino, MD, and Chadrick E. Denlinger, MD, Charleston, SCEsophagopericardial fistulas are rarely reported but carry a
high mortality. They can arise from a variety of conditions,
but most (75%) have a benign etiology.1 Candida esopha-
gitis is known to cause complications such as stricture, hem-
orrhage, and tracheoesophageal fistula.2 We present a case
of esophagopericardial fistula associated with Candida
esophagitis in a patient with advanced human immunodefi-
ciency virus (HIV) infection.
CLINICAL SUMMARY
A 37-year-old man with a history of HIV infection and
noncompliance with antiretroviral medications reportedchest pain and nausea. His CD4 count was 43 cells/mm3,
and the viral load was 17,000 copies/mL. An electrocardio-
gram showed diffuse ST-segment elevation, consistent with
pericarditis. An esophagogram revealed a large communi-
cation between the esophagus and pericardium (Figure 1).
A chest radiograph showed a pneumopericardium
(Figure 2). Esophagogastroduodenoscopy 2 weeks previ-
ously had shown only esophagitis, without evidence of a
stricture.
Because of the uncertainty of the fistula’s location, a right
thoracotomy was performed. The pericardium was opened,
and 500 mL of purulent fluid was drained. Cultures later
grew Candida krusei and a-hemolytic Streptococcus spe-
cies. Further inspection revealed a 3-cm opening on the
posterolateral wall of the esophagus near the gastroesopha-
geal junction. The esophagus was closed around an 18F
biliary T-tube with the side arm exiting through the perfora-
tion and advanced inside a 28F chest tube. Additional drains
were placed in the pericardium and pleural space; no
attempt was made to close the pericardium. Gastrostomy
and jejunostomy tubes were placed.m the distal esophagus (A), which quickly filled the pericardial sac (B).
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